

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20251C
APPLICATION NO.
10/001,755
APPLICANT
TAYLOR ET AL.
FILING DATE
OCTOBER 24, 2001Group
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
CY	AA	4,414,150	11/8/83	Goeddel	260	112.5	2/23/81
CY	AB	4,855,090	8/8/89	Wallach	264	4.1	7/28/87
CY	AC	4,997,652	3/5/91	Wong	424	428	5/31/89
CY	AD	5,023,087	6/11/91	Yau-Young	424	450	5/12/89
CY	AE	5,077,057	12/31/91	Szoka, Jr.	424	450	10/29/90
CY	AF	5,089,400	2/18/92	Meyer	435	69.51	3/7/89
CY	AG	5,609,868	3/11/97	Lowther et al.	424	857	8/10/94
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
CY	AM	009 842	4/16/80	Europe			<input type="checkbox"/> <input type="checkbox"/>
CY	AN	051 873 A2	5/19/82	Europe			<input type="checkbox"/> <input type="checkbox"/>
CY	AO	141 484	5/15/85	Europe			<input type="checkbox"/> <input type="checkbox"/>
CY	AP	205 404	12/17/86	Europe			<input type="checkbox"/> <input type="checkbox"/>
CY	AQ	329 609	8/23/89	Europe			<input type="checkbox"/> <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

CY	AR	Eppstein, "Altered Pharmacologic Properties of Liposome-Associated Human Interferon-Alpha. II.", J. Interferon Res., Vol. 2, No. 2, pp. 117-125 (1982).
CY	AS	Eppstein et al., "Altered Pharmacological Properties of Liposome-Associated Human Interferon-Alpha", J. Virol., Vol. 41, No. 2, pp. 575-582 (1982).
CY	AT	Eppstein et al., "Binding and Capture of Human Interferon-Alpha by Reverse Evaporation Vesicles, Multilamellar Vesicles, and Small Unilamellar Vesicles", J. Interferon Res., Vol. 1, No. 4, pp. 495-504 (1981).

EXAMINER

CHRISTOPHER YAEN

DATE CONSIDERED

10.22.03

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20251C
APPLICATION NO.
10/001,755
APPLICANT
TAYLOR ET AL.
FILING DATE
OCTOBER 24, 2001

Group
1642**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
CY	AA	331 635	9/6/89	Europe			<input type="checkbox"/>	<input type="checkbox"/>
CY	AB	799 027 B1	8/10/97	Europe			<input type="checkbox"/>	<input type="checkbox"/>
CY	AC	2,157,172	10/23/85	United Kingdom			<input type="checkbox"/>	<input type="checkbox"/>
CY	AD	WO 95/20379	8/3/95	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AE						<input type="checkbox"/>	<input type="checkbox"/>
	AF						<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

CHRISTOPHER YEAH

DATE CONSIDERED

10.22.03

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20251C
APPLICATION NO.
10/001,755
APPLICANT
TAYLOR ET AL.
FILING DATE
OCTOBER 24, 2001

Group
1642**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)**

CY	AA	Meister et al., "Biological Activities and Receptor Binding of Two Human Recombinant Interferons and Their Hybrids", J. Gen. Virol., Vol. 67, pp. 1633-1643 (1986).
CY	AB	Pestka, "The Human Interferons -- From Protein Purification and Sequence to Cloning and Expression in Bacteri: Before, Between, and Beyond", Arch. Biochem. Biophys., Vol. 221, No. 1, pp. 1-37 (1983).
CY	AC	Rehberg et al., "Specific Molecular Activities of Recombinant and Hybrid Leukocyte Interferons", J. Biolog. Chem., Vol. 257, No. 19, pp. 11497-11502 (1982).
CY	AD	Smith et al., "Antiviral and Antiproliferative Properties of Liposome-Associated Human Interferon-γ", J. Interferon Res., Vol. 10, pp. 153-160 (1990).
CY	AE	Smith, "Liposome-Associated Human Beta and Gama Interferons: Preparation and Demonstration of Their in vitro Antiviral, Anticellular and Immunomodulatory Properties", (1988) - Abstract ISSN 0419-4217.
CY	AF	Trunkey, "Trauma", Scientific American, Vol. 249, No. 2, pp. 28-35 (1983).
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

CHRISTOPHER YAEN

DATE CONSIDERED

10.22.03

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.